# Molecularly Tailored Therapy for Pancreas Cancer

> **NCT01888978** · PHASE2 · COMPLETED · sponsor: **Georgetown University** · enrollment: 19 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gem-OX
- **DRUG:** Gem-5FU
- **DRUG:** Gem-Tax
- **DRUG:** Modified FOLFOX-6
- **DRUG:** Ox-Tax
- **DRUG:** FOLFIRI
- **DRUG:** Tax-Iri

## Key facts

- **NCT ID:** NCT01888978
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2016-06
- **Final completion:** 2018-01-24
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888978, "Molecularly Tailored Therapy for Pancreas Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01888978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*